© 1995 American Heart Association, Inc.
Articles |
Immunological Evidence for the Presence of Advanced Glycosylation End Products in Atherosclerotic Lesions of Euglycemic Rabbits
From the Department of Medicine, University of California, San Diego, La Jolla, Calif (W.P., S.W.B., E.M., J.L.W.); the Diabetes Research Institute, University of Düsseldorf, Germany (T.K.); and The Picower Institute for Medical Research, Manhasset, NY (H.V., A.C.).
Abstract Atherosclerosis is known to be accelerated in diabetic patients, but the mechanisms of this acceleration are poorly understood. Nonenzymatic glycosylation of long-lived proteins results in the formation of advanced glycosylation end products (AGEs), which are extensively cross-linked and could contribute to atherogenesis. Oxidative modification of LDL is also an important process in atherogenesis. In vitro evidence suggests that hyperglycemia may enhance lipid peroxidation, and conversely, that increased lipid peroxidation may enhance AGE formation. If such interactions occur in vivo, we hypothesized that AGE should be found in atherosclerotic lesions of euglycemic LDL receptor–deficient rabbits in areas rich in lipids and oxidized lipoproteins. To demonstrate the presence of AGEs, we developed antisera against a specific "model" compound of AGE, 2-furoyl-4(5)-(2-furanyl)-1H-imidazole (FFI) by using FFI–hexanoic acid (FFI-HA)–protein adducts as the antigen and against AGEs in general by using AGE-albumin as the antigen. Antisera generated with FFI-HA–protein adducts recognized FFI-HA alone as well as FFI-protein adducts. Native proteins or proteins conjugated with aldehydes formed during lipid peroxidation in vitro were not recognized by these antisera. Immunocytochemistry with both FFI-specific and AGE-specific antisera revealed the presence of these epitopes in atherosclerotic lesions of euglycemic LDL receptor–deficient rabbits but not in normal aortic tissues. AGE epitopes within atherosclerotic lesions were predominantly found in similar locations as epitopes generated during modification of the lipoproteins by oxidation, consistent with the hypothesized interactions between oxidation and glycosylation. Indirect evidence in support of the in vivo presence of FFI-like structures was also obtained by the observation that both diabetic and euglycemic human subjects contained autoantibodies that recognize FFI-protein adducts. Taken together, these data provide immunological evidence for the in vivo presence of FFI-like structures and other AGE-protein adducts in atherosclerotic lesions, even in euglycemic conditions.
Key Words: advanced glycosylation end products • arteriosclerosis • immunocytochemistry • oxidation • autoantibodies
This article has been cited by other articles:
 |
|
 |
|
  M. Alikhani, C. M. MacLellan, M. Raptis, S. Vora, P. C. Trackman, and D. T. Graves Advanced glycation end products induce apoptosis in fibroblasts through activation of ROS, MAP kinases, and the FOXO1 transcription factor Am J Physiol Cell Physiol, February 1, 2007; 292(2): C850 - C856. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Alikhani, M. Alikhani, C. M. Boyd, K. Nagao, P. C. Trackman, and D. T. Graves Advanced Glycation End Products Enhance Expression of Pro-apoptotic Genes and Stimulate Fibroblast Apoptosis through Cytoplasmic and Mitochondrial Pathways J. Biol. Chem., April 1, 2005; 280(13): 12087 - 12095. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. S. Lim, R. J. MacFadyen, and G. Y. H. Lip Diabetes Mellitus, the Renin-Angiotensin-Aldosterone System, and the Heart Arch Intern Med, September 13, 2004; 164(16): 1737 - 1748. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Virella, S. R. Thorpe, N. L. Alderson, E. M. Stephan, D. Atchley, F. Wagner, and M. F. Lopes-Virella Autoimmune response to advanced glycosylation end-products of human LDL J. Lipid Res., March 1, 2003; 44(3): 487 - 493. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. F. Brizzi, P. Dentelli, R. Gambino, S. Cabodi, M. Cassader, A. Castelli, P. Defilippi, L. Pegoraro, and G. Pagano STAT5 Activation Induced by Diabetic LDL Depends on LDL Glycation and Occurs Via src Kinase Activity Diabetes, November 1, 2002; 51(11): 3311 - 3317. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Miyata, C. van Ypersele de Strihou, Y. Ueda, K. Ichimori, R. Inagi, H. Onogi, N. Ishikawa, M. Nangaku, and K. Kurokawa Angiotensin II Receptor Antagonists and Angiotensin-Converting Enzyme Inhibitors Lower In Vitro the Formation of Advanced Glycation End Products: Biochemical Mechanisms J. Am. Soc. Nephrol., October 1, 2002; 13(10): 2478 - 2487. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. S. Collison, R. S. Parhar, S. S. Saleh, B. F. Meyer, A. A. Kwaasi, M. M. Hammami, A. M. Schmidt, D. M. Stern, and F. A. Al-Mohanna RAGE-mediated neutrophil dysfunction is evoked by advanced glycation end products (AGEs) J. Leukoc. Biol., March 1, 2002; 71(3): 433 - 444. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Bierhaus, S. Schiekofer, M. Schwaninger, M. Andrassy, P. M. Humpert, J. Chen, M. Hong, T. Luther, T. Henle, I. Kloting, et al. Diabetes-Associated Sustained Activation of the Transcription Factor Nuclear Factor-{kappa}B Diabetes, December 1, 2001; 50(12): 2792 - 2808. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. E. Mullick, B. A. Walsh, K. M. Reiser, and J. C. Rutledge Chronic estradiol treatment attenuates stiffening, glycoxidation, and permeability in rat carotid arteries Am J Physiol Heart Circ Physiol, November 1, 2001; 281(5): H2204 - H2210. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M.-P. Wautier, O. Chappey, S. Corda, D. M. Stern, A. M. Schmidt, and J.-L. Wautier Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE Am J Physiol Endocrinol Metab, May 1, 2001; 280(5): E685 - E694. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Sakata, N. Uesugi, S. Takebayashi, R. Nagai, T. Jono, S. Horiuchi, M. Takeya, H. Itabe, T. Takano, T. Myint, et al. Glycoxidation and lipid peroxidation of low-density lipoprotein can synergistically enhance atherogenesis Cardiovasc Res, February 1, 2001; 49(2): 466 - 475. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Tsimikas, W. Palinski, and J. L. Witztum Circulating Autoantibodies to Oxidized LDL Correlate With Arterial Accumulation and Depletion of Oxidized LDL in LDL Receptor-Deficient Mice Arterioscler Thromb Vasc Biol, January 1, 2001; 21(1): 95 - 100. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. M Crauwels, A. G Herman, and H. Bult Local application of advanced glycation end products and intimal hyperplasia in the rabbit collared carotid artery Cardiovasc Res, July 1, 2000; 47(1): 173 - 182. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Kislinger, C. Fu, B. Huber, W. Qu, A. Taguchi, S. Du Yan, M. Hofmann, S. F. Yan, M. Pischetsrieder, D. Stern, et al. Nepsilon -(Carboxymethyl)Lysine Adducts of Proteins Are Ligands for Receptor for Advanced Glycation End Products That Activate Cell Signaling Pathways and Modulate Gene Expression J. Biol. Chem., October 29, 1999; 274(44): 31740 - 31749. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Merat, F. Casanada, M. Sutphin, W. Palinski, and P. D. Reaven Western-Type Diets Induce Insulin Resistance and Hyperinsulinemia in LDL Receptor-Deficient Mice But Do Not Increase Aortic Atherosclerosis Compared With Normoinsulinemic Mice in Which Similar Plasma Cholesterol Levels Are Achieved by a Fructose-Rich Diet Arterioscler Thromb Vasc Biol, May 1, 1999; 19(5): 1223 - 1230. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Schmidt, S. D. Yan, J.-L. Wautier, and D. Stern Activation of Receptor for Advanced Glycation End Products : A Mechanism for Chronic Vascular Dysfunction in Diabetic Vasculopathy and Atherosclerosis Circ. Res., March 19, 1999; 84(5): 489 - 497. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Du Yan, Y. Shi, A. Zhu, J. Fu, H. Zhu, Y. Zhu, L. Gibson, E. Stern, K. Collison, F. Al-Mohanna, et al. Role of ERAB/L-3-Hydroxyacyl-coenzyme A Dehydrogenase Type II Activity in Abeta -induced Cytotoxicity J. Biol. Chem., January 22, 1999; 274(4): 2145 - 2156. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Bierhaus, M. A Hofmann, R. Ziegler, and P. P Nawroth AGEs and their interaction with AGE-receptors in vascular disease and diabetes mellitus. I. The AGE concept Cardiovasc Res, March 1, 1998; 37(3): 586 - 600. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Bierhaus, T. Illmer, M. Kasper, T. Luther, P. Quehenberger, H. Tritschler, P. Wahl, R. Ziegler, M. Muller, and P. P. Nawroth Advanced Glycation End Product (AGE)–Mediated Induction of Tissue Factor in Cultured Endothelial Cells Is Dependent on RAGE Circulation, October 7, 1997; 96(7): 2262 - 2271. [Abstract] [Full Text]
|
|
|
|
|
|
P. Reaven, S. Merat, F. Casanada, M. Sutphin, and W. Palinski Effect of Streptozotocin-Induced Hyperglycemia on Lipid Profiles, Formation of Advanced Glycation Endproducts in Lesions, and Extent of Atherosclerosis in LDL Receptor-Deficient Mice Arterioscler Thromb Vasc Biol, October 1, 1997; 17(10): 2250 - 2256. [Abstract] [Full Text]
|
|
|
|
|
|
J. Fruebis, V. Gonzalez, M. Silvestre, and W. Palinski Effect of Probucol Treatment on Gene Expression of VCAM-1, MCP-1, and M-CSF in the Aortic Wall of LDL Receptor–Deficient Rabbits During Early Atherogenesis Arterioscler Thromb Vasc Biol, July 1, 1997; 17(7): 1289 - 1302. [Abstract] [Full Text]
|
|
|
|
|
|
M.-X. Fu, J.ús R. Requena, A. J. Jenkins, T. J. Lyons, J. W. Baynes, and S. R. Thorpe The Advanced Glycation End Product, N[IMAGE]-(Carboxymethyl)lysine, Is a Product of both Lipid Peroxidation and Glycoxidation Reactions J. Biol. Chem., April 26, 1996; 271(17): 9982 - 9986. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Basta, G. Lazzerini, M. Massaro, T. Simoncini, P. Tanganelli, C. Fu, T. Kislinger, D. M. Stern, A. M. Schmidt, and R. De Caterina Advanced Glycation End Products Activate Endothelium Through Signal-Transduction Receptor RAGE: A Mechanism for Amplification of Inflammatory Responses Circulation, February 19, 2002; 105(7): 816 - 822. [Abstract] [Full Text] [PDF]
|
|